Structure Based Drug Discovery

In a recent breakthrough in AI-driven drug discovery, researchers from Pfizer, AstraZeneca, and Chalmers University unveiled a new generative framework called FLOWR, designed to revolutionize structure-based ligand generation. Their collaborative work bridges machine learning, computational chemistry, and pharmaceutical research and is set to address some of the most persistent challenges in early-stage drug design. Why…